Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2024-04-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
盈康生命科技股份有限公司与国泰君安证券股份有限公司关于申请向特定对象发行股票的审核问询函的回复（修订稿）
Regulatory Filings Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shenzhen Stock Exchange regarding a company's application for a private placement of shares. It includes extensive disclosures about the company's medical and healthcare business operations, compliance with regulations, and platform economy considerations. The document is lengthy (15,000 characters) and contains substantive content addressing regulatory questions, not merely an announcement or a brief summary. It is not a financial report like an annual or quarterly report, nor is it an earnings release or a call transcript. It is a regulatory filing responding to a specific inquiry letter from the exchange, which fits the category of Regulatory Filings (RNS).
2024-04-11 Chinese
关于向特定对象发行股票的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Yingkang Life Technology Co., Ltd. regarding the company's response to a review inquiry letter from the Shenzhen Stock Exchange about a proposed private placement of shares. It discusses updates to the prospectus and application documents related to the issuance of shares to specific investors. The document does not contain financial statements or detailed financial data but rather informs about the regulatory review process and updates to application materials. It is an announcement related to capital raising activities but not the actual financing report or detailed financial results. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or a certification. Hence, the classification is CAP with high confidence.
2024-04-11 Chinese
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document" related to a specific stock issuance by 盈康生命科技股份有限公司. It is issued by 国泰君安证券股份有限公司 as the sponsor for a specific private placement of shares (向特定对象发行股票). The document contains detailed information about the issuer, the issuance plan, financial data, risk factors, and regulatory compliance references. It is a comprehensive document related to a capital raising event through a private placement of shares. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. It is not an annual or interim report, nor an earnings release or proxy statement. The document length is substantial and contains substantive financial and issuance details, not merely an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-04-11 Chinese
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" which translates to "Sponsorship Letter for Stock Issuance" or "Issuance Sponsorship Document". It is issued by Guotai Junan Securities Co., Ltd. as the sponsor for a specific stock issuance by Yingkang Life Technology Co., Ltd. The document contains detailed information about the stock issuance, the sponsor's responsibilities, legal compliance, internal review procedures, and financial data of the issuer. It is a formal document related to the underwriting and sponsorship of a specific stock issuance to particular investors (non-public offering). This type of document is not a general annual report, earnings release, or a regulatory filing announcement. It is a detailed sponsorship report related to capital raising activities. According to the filing definitions, updates on company fundraising, financing activities, or capital structure changes fall under "Capital/Financing Update (CAP)". This document is a comprehensive sponsorship report for a specific stock issuance, which is a capital raising event. Therefore, the most appropriate classification is CAP (Capital/Financing Update). The document length is substantial (15,000 characters), and it contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to the clear context and content.
2024-04-11 Chinese
和信会计师事务所(特殊普通合伙)关于盈康生命科技股份有限公司申请向特定对象发行股票的审核问询函回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shenzhen Stock Exchange regarding a company's application for a specific share issuance. It contains extensive financial data, business analysis, and risk disclosures related to goodwill impairment tests for subsidiaries, detailed operational and market environment descriptions, and compliance with regulatory requirements. The document is not a full annual or interim financial report but rather a regulatory filing responding to an official inquiry letter (审核问询函). It includes audit firm involvement and legal opinions but is primarily a regulatory compliance document addressing specific questions from the exchange about the share issuance application. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance document responding to a regulatory inquiry rather than a standalone audit report, annual report, or other specific report types.
2024-04-11 Chinese
北京市金杜律师事务所关于盈康生命科技股份有限公司向特定对象发行股票的补充法律意见书(一)
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion and supplementary legal opinion issued by a law firm (北京市金杜律师事务所) regarding a company's (盈康生命科技股份有限公司) specific issuance of shares to particular investors. It extensively discusses regulatory compliance, legal qualifications, and operational details related to the issuance of A shares to specific objects. The document references regulatory inquiries (审核问询函), legal standards, and compliance with Chinese securities laws and regulations. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital issuance process. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-04-11 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.